Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Nebivolol 1 Clear all

Conditions: Hypertension
Interventions: Nebivolol, Lisinopril; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Atherosclerosis, Endothelial Function
Interventions: Nebivolol, Atenolol; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 79 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hypertension
Interventions: Metoprolol, Nebivolol; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Angina Pectoris, Microvascular Angina, Vasospastic Angina, Myocardial Bridge of Coronary Artery
Interventions: Amlodipine, Nebivolol, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions: Placebo, Nebivolol 5 mg, metoprolol tartrate 50 mg, Sildenafil25 mg; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Peripheral Artery Disease, Hypertension
Interventions: nebivolol, Metoprolol succinate; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: Metoprolol succinate, Nebivolol, Non-invasive measurement of Cardiac Output (CO), Endothelial cell collection, Microvascular perfusion assessment using Definity; Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension
Interventions: Nebivolol; Drug
Lead sponsor: Mercy Research; Other
Eligibility: 18 Years to 90 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hypertension
Interventions: Nebivolol, Valsartan and Hydrochlorothiazide; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 812 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 135
States / cities: Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 113 more

Conditions: Hypertension
Interventions: Nebivolol, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 54 Years
Enrollment: 641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 75
States / cities: Phoenix, Arizona • Buena Park, California • Burbank, California + 58 more

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Nebivolol Ophthalmic Suspension 1 Percent, Nebivolol Ophthalmic Suspension 0.5 Percent, Timolol Ophthalmic Suspension 0.5 Percent, Timolol Ophthalmic Solution 0.5 Percent; Drug
Lead sponsor: Betaliq, Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Hypertension
Interventions: Nebivolol; Drug
Lead sponsor: Mylan Bertek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Stage 1 Hypertension, Stage 2 Hypertension
Interventions: Nebivolol and Valsartan 1, Nebivolol and Valsartan 2, Nebivolol and Valsartan 3, Nebivolol 1, Nebivolol 2, Valsartan 1, Valsartan 2, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 4,161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 413
States / cities: Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 290 more

Conditions: Hypertension
Interventions: Nebivolol, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 26
States / cities: Chandler, Arizona • Phoenix, Arizona • Los Angeles, California + 20 more

Conditions: Hypertension
Interventions: Nebivolol, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 36
States / cities: Foley, Alabama • Montgomery, Alabama • Chino, California + 30 more

Conditions: Hypertension, Type 2 Diabetes Mellitus
Interventions: Nebivolol, Metoprolol ER, HCTZ; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 62
States / cities: Athens, Alabama • Huntsville, Alabama • Bell Gardens, California + 54 more

Conditions: Hypertension
Interventions: Metoprolol, Nebivolol; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Central Aortic Pressure
Interventions: Nebivolol, Metoprolol; Drug
Lead sponsor: Creighton University; Other
Eligibility: 45 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Hypertension
Interventions: Nebivolol and Atenolol; Drug
Lead sponsor: Mylan Bertek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Stage 2 Diastolic Hypertension
Interventions: nebivolol and lisinopril (free combination), nebivolol monotherapy, lisinopril monotherapy, placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 664 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 89
States / cities: Scottsdale, Arizona • Tempe, Arizona • Tucson, Arizona + 69 more

Conditions: Cardiac Amyloidosis, Heart Diseases, TTR Cardiac Amyloidosis
Interventions: Beta blocker; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 65 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension
Interventions: Nebivolol, atenolol, placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hypertension
Interventions: Nebivolol; Drug
Lead sponsor: Mylan Bertek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Hypertension
Interventions: Nebivolol, Atenolol, Moxifloxacin; Drug
Lead sponsor: Mylan Bertek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Blood Pressure Effects of Nebivolol Versus Lisinopril in New Onset or Worsening Hypertension Induced by Bevacizumab

Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Plaques

Nebivolol Versus Metoprolol: Comparative Effects on Fatigue and Quality of Life

Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries

Nebivolol in the Supine Hypertension of Autonomic Failure

Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure

Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients

Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function

Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension

Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)

Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension

A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive Patients

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy

Nebivolol in Patients With Systolic Stage 2 Hypertension

Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients

Comparing the Effects of Two Beta Blockers,Metoprolol and Nebivolol,on Ambulatory Blood Pressure and Basal Metabolic Rate

Impact of Nebivolol on Central Aortic Pressure

A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension

Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension

N-of-1 for Beta-Blockers in Cardiac Amyloidosis

A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function

Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension

A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo